Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 11/20 | 0.54 |
| ▸ | PI4KA | P42356 | 2/20 | 0.53 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.53 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.42 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2509052 | 0.84 | MAP4K4 (0.68) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL6096033 | 0.79 | PI4KA (0.57) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL29663392 | 0.79 | PI4KA (0.57) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL5453911 | 0.79 | EGFR (0.46) | MAP4K4EGFRESR1ESR2 | |
| SCHEMBL16755291 | 0.76 | PI4KA (0.53) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20813449 | 0.76 | EGFR (0.44) | MAP4K4EGFRESR1ESR2 | |
| SCHEMBL6442231 | 0.76 | NR4A2 (0.56) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL7376295 | 0.76 | MAP4K4 (0.54) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL5465224 | 0.76 | PDE4A (0.53) | MAP4K4EGFRESR1ESR2 | |
| SCHEMBL29728044 | 0.76 | MAP4K4 (0.59) | MAP4K4PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107641115-A | The preparation method of Barasertib | 胡张艳 | 2018-01-30 | — | — | CN | claimed |
| CN-110115365-A | The adjusting that actinism receptor and relative ligand are carried out | 西诺米克斯公司 | 2019-08-13 | — | — | CN | disclosed |
| CN-107641115-A | The preparation method of Barasertib | 胡张艳 | 2018-01-30 | — | — | CN | disclosed |
| CN-101779124-B | Modulation of chemosensory receptors and ligands associated therewith | 西诺米克斯公司 | 2017-12-12 | — | — | CN | disclosed |
| CN-107365319-A | The regulation carried out to actinism acceptor and relative part | 西诺米克斯公司 | 2017-11-21 | — | — | CN | disclosed |
| US-7498335-B2 | Method of producing an antiangiogenic or vascular permeability reducing effect | ASTRAZENECA AB (CH) | 2009-03-03 | — | — | US | disclosed |
| EP-1218353-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2007-10-17 | — | — | EP | disclosed |
| EP-1272185-B1 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-6806274-B1 | IMMUNOREGULATION OR IMMUNOSUPPRESSIVE AGENTS; TYROSINE KINASE INHIBITORS; PREVENTING ORGAN TRANSPLANT REJECTION; AUTOIMMUNE CONDITIONS; REDUCED SIDE EFFECTS | ASTRAZENECA UK LIMITED (GB) | 2004-10-19 | — | — | US | disclosed |
| US-20030225111-A1 | Therapy | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | disclosed |
| EP-1272185-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2003-01-08 | — | — | EP | disclosed |
| CN-1360582-A | Quinazoline derivs. | ASTRAZENECA UK LTD (GB) | 2002-07-24 | — | — | CN | disclosed |
| EP-1218353-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca UK Limited (GB) | 2002-07-03 | — | — | EP | disclosed |
| WO-2002002534-A1 | QUINAZOLINES WITH THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2002-01-10 | — | — | WO | disclosed |
| WO-2001066099-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001004102-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225111-A1 | Therapy | VEGFA, AQP1, FLT1 | MAP4K4 3090/4885PI4KA 3871/4885PI4K2B 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.